These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 12868117)

  • 21. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research.
    Ali BH; Al Moundhri MS
    Food Chem Toxicol; 2006 Aug; 44(8):1173-83. PubMed ID: 16530908
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cisplatin and hypomagnesemia.
    Lajer H; Daugaard G
    Cancer Treat Rev; 1999 Feb; 25(1):47-58. PubMed ID: 10212589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine.
    Sastry J; Kellie SJ
    Pediatr Hematol Oncol; 2005; 22(5):441-5. PubMed ID: 16020136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Time dependent protection of amifostine from renal and hematopoietic cisplatin induced toxicity.
    Asna N; Lewy H; Ashkenazi IE; Deutsch V; Peretz H; Inbar M; Ron IG
    Life Sci; 2005 Mar; 76(16):1825-34. PubMed ID: 15698860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renal and electrolyte disturbances associated with cisplatin.
    Blachley JD; Hill JB
    Ann Intern Med; 1981 Nov; 95(5):628-32. PubMed ID: 7027859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protection by ozone preconditioning is mediated by the antioxidant system in cisplatin-induced nephrotoxicity in rats.
    Borrego A; Zamora ZB; González R; Romay C; Menéndez S; Hernández F; Montero T; Rojas E
    Mediators Inflamm; 2004 Feb; 13(1):13-9. PubMed ID: 15203559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal impairment and hypertension in brain tumor patients treated in childhood are mainly associated with cisplatin treatment.
    Pietilä S; Ala-Houhala M; Lenko HL; Harmoinen AP; Turjanmaa V; Mäkipernaa A
    Pediatr Blood Cancer; 2005 Apr; 44(4):363-9. PubMed ID: 15586356
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update.
    dos Santos NA; Carvalho Rodrigues MA; Martins NM; dos Santos AC
    Arch Toxicol; 2012 Aug; 86(8):1233-50. PubMed ID: 22382776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cisplatin-induced renal toxicity magn…ified: role of magnesium deficiency in AKI onset.
    Romani AM
    Am J Physiol Renal Physiol; 2015 Dec; 309(12):F1005-6. PubMed ID: 26511648
    [No Abstract]   [Full Text] [Related]  

  • 30. The role of mannitol as a nephroprotectant in patients receiving cisplatin therapy.
    Morgan KP; Buie LW; Savage SW
    Ann Pharmacother; 2012 Feb; 46(2):276-81. PubMed ID: 22298599
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [About side effects of platinum drugs].
    Waszkiewicz K
    Postepy Hig Med Dosw; 2001; 55(3):387-406. PubMed ID: 11505639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Magnesium depletion enhances cisplatin-induced nephrotoxicity.
    Lajer H; Kristensen M; Hansen HH; Nielsen S; Frøkiaer J; Ostergaard LF; Christensen S; Daugaard G; Jonassen TE
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):535-42. PubMed ID: 15947931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amifostine for children with medulloblastoma treated with cisplatin-based chemotherapy.
    Fisher MJ; Lange BJ; Needle MN; Janss AJ; Shu HK; Adamson PC; Phillips PC
    Pediatr Blood Cancer; 2004 Dec; 43(7):780-4. PubMed ID: 15390300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Amifostine as a supporting treatment during cancer therapy].
    Jantunen E; Puistola U
    Duodecim; 1999; 115(11):1223-7. PubMed ID: 11877841
    [No Abstract]   [Full Text] [Related]  

  • 35. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care.
    Launay-Vacher V; Rey JB; Isnard-Bagnis C; Deray G; Daouphars M;
    Cancer Chemother Pharmacol; 2008 May; 61(6):903-9. PubMed ID: 18317762
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cisplatin nephrotoxicity is mediated by gamma glutamyltranspeptidase, not via a C-S lyase governed biotransformation pathway.
    Wainford RD; Weaver RJ; Stewart KN; Brown P; Hawksworth GM
    Toxicology; 2008 Jul; 249(2-3):184-93. PubMed ID: 18583013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amifostine increases cure rate of cisplatin on ascites hepatoma 22 via selectively protecting renal thioredoxin reductase.
    Zhang J; Wang X; Lu H
    Cancer Lett; 2008 Feb; 260(1-2):127-36. PubMed ID: 18039557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypomagnesemia: renal magnesium handling.
    Kelepouris E; Agus ZS
    Semin Nephrol; 1998 Jan; 18(1):58-73. PubMed ID: 9459289
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Study of cisplatin-vinblastine plus amifostine in patients with locally advanced or metastatic non-small cell lung cancer.
    Thongprasert S; Chewaskulyong B
    J Med Assoc Thai; 2004 Oct; 87(10):1162-7. PubMed ID: 15560691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cisplatin induced damage in kidney genomic DNA and nephrotoxicity in male rats: the protective effect of grape seed proanthocyanidin extract.
    Saad AA; Youssef MI; El-Shennawy LK
    Food Chem Toxicol; 2009 Jul; 47(7):1499-506. PubMed ID: 19351554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.